Current concepts in the diagnosis and management of cytokine release syndrome.

By Daniel W. Lee, R. Gardner, D. Porter, C. Louis, N. Ahmed, M. Jensen, S. Grupp, C. Mackall. Blood, 2014

2,536 citations recorded by the source corpus.

Subfields: Immunology, Neurology, Oncology

View Paper: https://www.semanticscholar.org/paper/66147a0f8ee0d12985906c24cec516cfaf4aae3e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. J. Kochenderfer
2. C. June
3. Jennifer N. Brudno
4. K. Peggs
5. Wendell A. Lim
6. C. Mackall
7. K. Rezvani

In Oncology

1. J. Kochenderfer
2. Jennifer N. Brudno
3. C. June
4. Wendell A. Lim
5. S. Grupp
6. S. Maude
7. D. Teachey
8. D. Porter

Citations in the corpus

• COVID-19: what has been learned and to be learned about the novel coronavirus disease (2020, background): “For example, antibodies can overstimulate the immune response and cause cytokine release syndrome, which is potentially a life-threatening toxicity [84] .”
• Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells (2017, neutral): “Not white 18 (78) 3 (13) 2 (9) 23 Prior therapies Median (range) 4 (1–11) 4 (1–10) 4 (1–11) 4 (1–11) 0.”
• CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. (2015, background): “Based on our successful use of this drug, other groups have replicated these results.(25,27,67) The majority of patients treated with tocilizumab have rapid and complete resolution of CRS after a single dose, although a minority of the patients we have treated with severe CRS require a second dose w”
• New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management (2017, background): “An improvement of neurotoxicity was not observed in affected patients after the administration of this anti-IL6 antibody [1, 9].”
• Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma (2019, neutral): “Thrombocytopenia 19 (58) 5 (15) 10 (30)”
• Chimeric antigen receptor T-cell therapy — assessment and management of toxicities (2018, methodology): “High‐dose vasopressors are defined as any of the following (as reported by Lee et al.(30)): noradrenaline ≥20 μg/min; dopamine ≥10 μg/kg/min; phenylephrine ≥200 μg/min; adrenaline ≥10 μg/min; if on vasopressin, vasopressin plus noradrenaline equivalent of ≥10 μg/min; and if on combination vasopresso”
• The Principles of Engineering Immune Cells to Treat Cancer (2017, background): “Cytokine release syndrome occurs more frequently in patients with higher disease burdens at time of infusion and rapidly resolves after cytokine directed therapy that targets IL-6 (Lee et al., 2014).”
• CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. (2016, background): “The administration of CD19 CAR–T cells and their subsequent expansion can be associated with cytokine release syndrome (CRS), characterized by hyperpyrexia, hypotension, capillary leak, neurotoxicity, and death in severe cases (3, 4, 7, 9, 10).”
• T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. (2018, methodology): “Cytokine-release syndrome (CRS) was graded as described.(33) Ex Vivo Assays Immunohistochemistry, flow cytometry including minimal residual disease (MRD) detection by eight-color flow cytometry, quantitative polymerase chain reaction, cytokine assays, and statistical comparisons were performed as de”